Author: Sorokin, Alexander V.; Karathanasis, Sotirios K.; Yang, Zhiâ€Hong; Freeman, Lita; Kotani, Kazuhiko; Remaley, Alan T.
Title: COVIDâ€19—Associated dyslipidemia: Implications for mechanism of impaired resolution and novel therapeutic approaches Cord-id: bl6obu2v Document date: 2020_6_26
ID: bl6obu2v
Snippet: The current coronavirus disease 2019 (COVIDâ€19) pandemic presents a global challenge for managing acutely ill patients and complications from viral infection. Systemic inflammation accompanied by a “cytokine storm,†hemostasis alterations and severe vasculitis have all been reported to occur with COVIDâ€19, and emerging evidence suggests that dysregulation of lipid transport may contribute to some of these complications. Here, we aim to summarize the current understanding of the potential
Document: The current coronavirus disease 2019 (COVIDâ€19) pandemic presents a global challenge for managing acutely ill patients and complications from viral infection. Systemic inflammation accompanied by a “cytokine storm,†hemostasis alterations and severe vasculitis have all been reported to occur with COVIDâ€19, and emerging evidence suggests that dysregulation of lipid transport may contribute to some of these complications. Here, we aim to summarize the current understanding of the potential mechanisms related to COVIDâ€19 dyslipidemia and propose possible adjunctive type therapeutic approaches that modulate lipids and lipoproteins. Specifically, we hypothesize that changes in the quantity and composition of highâ€density lipoprotein (HDL) that occurs with COVIDâ€19 can significantly decrease the antiâ€inflammatory and antiâ€oxidative functions of HDL and could contribute to pulmonary inflammation. Furthermore, we propose that lipoproteins with oxidized phospholipids and fatty acids could lead to virusâ€associated organ damage via overactivation of innate immune scavenger receptors. Restoring lipoprotein function with ApoAâ€I raising agents or blocking relevant scavenger receptors with neutralizing antibodies could, therefore, be of value in the treatment of COVIDâ€19. Finally, we discuss the role of omegaâ€3 fatty acids transported by lipoproteins in generating specialized proresolving mediators and how together with antiâ€inflammatory drugs, they could decrease inflammation and thrombotic complications associated with COVIDâ€19.
Search related documents:
Co phrase search for related documents- abnormal coagulation and acute inflammation: 1, 2
- accumulation tg and acute inflammation: 1, 2
- acs acute coronary syndrome and acute condition: 1
- acs acute coronary syndrome and acute coronary syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active process and acute inflammation: 1
Co phrase search for related documents, hyperlinks ordered by date